Cardiovascular Systems Inc

Cardiovascular Systems — Q2 FY2021 Earnings Presentation

14 slides from Cardiovascular Systems's earnings presentation, Feb 3, 2021

  1. Slide 1: Q2 FY21 Earnings Supplement

    ©2020 Cardiovascular Systems, Inc. All Rights Reserved. Q2 FY21 Earnings Supplement February 3, 2021

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation r

  3. Slide 3: Q2 FY21 Revenues of $64.2 Million Highlights

    6.0% Sequential Quarterly Increase Q2 FY21 Revenues of $64.2 Million *Excludes $20.9M financing obligation for lease payments on company headquarters Q2 FY21 Revenue Breakdown U.S. Peripheral $43.9 U.S. Coronary $18.0 U.S. Peripheral U.S. Coronary International ($ in millions) International $2.3 • N

  4. Slide 4: New Information Introduced

    Q2 FY21: New Information Introduced 4 Slides 5 and 6 show Orbital Atherectomy System revenue, Interventional Support Device (ISD) revenue and U.S. Revenue by peripheral and coronary franchise Similar to coronary, we anticipate the launch of peripheral ISDs will become a key growth driver We provided

  5. Slide 5: Continued strength in office-based lab procedures

    Q2 FY21: U.S. Peripheral 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue. 2 Includes peripheral orbital atherectomy devices, ViperWire, ViperSlide, Exchangeable cartridges, ViperTrack and other 3 ViperCath and Zilient Guidewires Continued strength in o

  6. Slide 6: Strong recovery in coronary procedures

    Q2 FY21: U.S. Coronary 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue. 2 Includes coronary orbital atherectomy devices, Coronary Guidewire, ViperSlide and other 3 Includes Sapphire angioplasty balloons and Teleport microcatheters Strong recovery in co

  7. Slide 7: International: Maintaining strong market share in Japan

    Q2 FY21: International Maintaining strong market share in Japan 7 International revenue increased 32.0% sequentially • Ability to open new accounts and drive adoption outside the U.S. impacted by international travel restrictions and cath lab access restrictions since February 2020 • OAS launched in

  8. Slide 8: Q2 FY21 vs. Q1 FY21 and Q2 FY20

    Q2 FY21 vs. Q1 FY21 and Q2 FY20 Dollars in thousands 8 Q2 FY21 Q/Q Change Y/Y Change Total Revenue $64,169 6.0% -6.1% Worldwide Peripheral Revenue $43,956 2.4% -7.6% Worldwide Coronary Revenue $20,213 14.8% -2.6% US Revenue $61,907 5.2% -6.1% US Peripheral Revenue $43,924 2.3% -7.5% US Coronary Reve

  9. Slide 9: Select Financial Information

    Q2 FY21: Select Financial Information Dollars in thousands, except earnings per share 9 Q2 FY21 Q1 FY21 Q/Q Change Q2 FY20 Y/Y Change Net revenues $64,169 $60,544 $3,625 $68,334 ($4,165) Cost of goods sold 13,920 12,564 1,356 13,718 202 Gross Margin 78.3% 79.2% Declined 90 BP 79.9% Declined 160 BP S

  10. Slide 10: 2H FY21 Timeline

    2H FY21 Timeline O p e ra ti o n s In v e s to rs Q3 FY21 Announced partnership to develop new DCBs February 1 First patient in Europe treated with Diamondback 360® Coronary OAS February Q2 Earnings February 3 SVBLeerink Conference February 25 Raymond James Conference March 2 EU Launch Q3 Oppenheime

  11. Slide 11: Q3 FY21: Guidance

    Q3 FY21: Guidance For the fiscal 2021 third quarter ending March 31, 2021, CSI anticipates: Revenue of $60 million to $65 million, representing 98% to 106% of revenue from Q3 FY2020; Gross profit as a percentage of revenues in the 77% to 78% range; Operating expenses in a range of $52 to $54 million

  12. Slide 12: Non-GAAP Financial Measures

    Non-GAAP Financial Measures 12 CSI uses Adjusted EBITDA as a supplemental measure of performance and believes this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense

  13. Slide 13: Investor Contact

    Investor Contact: Jack Nielsen 651-202-4919 j.nielsen@csi360.com CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2021 Cardiovascular Systems, Inc. OrbusNeich®, Teleport® and Sapphire® are trademarks of Or

  14. Slide 14: Cardiovascular Systems, Inc.

    CARDIOVASCULAR SYSTEMS, INC. cS. www.csi360.com

Cardiovascular Systems — Q2 FY2021 Earnings Presentation on 6ix